CD274 and non-small cell lung carcinoma: Importantly, in 2016, pembrolizumab was approved as the first-line treatment of NSCLC patients with high PD-L1 expression based on the KEYNOTE-024 trial, which aimed to test its therapeutic effect on metastatic treatment-naive NSCLC (51, 54, 55).